News

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab ...
Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.
There is growing interest in the application of machine learning techniques in bioinformatics. The supervised machine learning approach has been widely applied to bioinformatics and gained a lot of ...
Video annotation is an effective way to facilitate content-based analysis for videos. Automatic machine learning methods are commonly used to accomplish this task. Among these, active learning is one ...
Ten men with severe hemophilia B received a single dose of scAAV2/8-LP1-hFIXco vector, administered through a peripheral vein, in one of three dose cohorts (low: 2×10 11 vector genomes [vg] per ...
In this paper, we face the problem of collecting training samples for regression problems under an active learning perspective. In particular, we propose various active learning strategies ...
Researchers in Spain sought to examine how family history influences diagnosis, treatment, and clinical outcomes in 1,208 children with severe hemophilia A who were born between 2000 and 2022. The ...
The latest Mount Etna eruption triggered an avalanche of volcanic material and sent ash miles into the air. Spectacular photos and videos capture the eruption of Europe's largest active volcano.
This framework helps educators design learning experiences where students don’t just study knowledge; they actively construct and apply it in meaningful contexts. The AAA model: at a glance • Active ...
Organic chemistry courses are often regarded as a bottleneck for undergraduates pursuing STEM- and health-related fields. This study reports a decade-long analysis of performance trends in two ...
Meta AI now has one billion monthly active users across its apps, CEO Mark Zuckerberg said at the company’s annual shareholder meeting on Wednesday, as first reported by CNBC.The new milestone ...